NEW YORK, April 4 (Reuters) - Valeant Pharmaceuticals (NYSE:VRX)
International Inc VRX.TO will cut its sales force for Addyi, a
treatment aimed at female sexual dysfunction, as well as some
employees who sell dermatology products, according to an
internal memo seen by Reuters.
The memo said that its contract with an outside sales force
ends on April 15 and will not be renewed. Addyi, which Valeant
purchased with the $1 billion acquisition of Sprout
Pharmaceuticals, has had slow sales since it was launched last
fall.
Bloomberg first reported the cuts.